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Abstract 
In this issue, Wright et al. describe an elegant approach to evaluate substrates and the drug target 
potential of Leishmania donovani N-myristoyltransferase (NMT) using a technically simple and 
straight-forward chemical proteomics approach (Wright et al., this issue). 
 
Main text 
The identification and validation of novel drug targets is often the first step in current drug discovery 
(Overington et al., 2006). Due to the high costs and risks as well as long development times, potential 
drug targets are stringently evaluated before a new drug discovery campaign is launched. Besides 
economic aspects such as favorable intellectual property situation or promising marketing 
opportunities, these evaluations naturally also involve the ͚suitaďility͛ of the drug target, suĐh as an 
assessment of its disease relevance or druggability (Gashaw et al., 2011). Obviously, such 
investigations are not for nothing but frequently require time, labor and cost intensive molecular, 
genetic and pharmacological studies.  
These issues weigh particularly heavy for the development of drugs vs. neglected tropical diseases, a 
family of biologically diverse disorders found in poorly developed tropical or subtropical regions. 
Despite an irrefutable unmet medical need, the weak marketing perspectives and low academic 
funding rates severely restrict the discovery of novel chemotherapeutics against these fatal diseases. 
However, neglected tropical disease drug development is not solely hampered by economic aspects 
but also due to a lack of suitable approaches to overcome these disorders (Nwaka and Hudson 2006). 
In fact, for many neglected tropical diseases, target identification as the starting point for drug 
discovery has been and still is a tedious and challenging task because molecular manipulations of the 
causing pathogens, disease models for target assessment or even a basic understanding of the 
underlying disease mechanisms are still limited.  
These challenges call for alternative complementary approaches. In the last years, chemical 
proteomics, an approach in which small molecule probes are used to covalently tag proteins in a 
function-dependent manner, has emerged into such a complementary technology for drug target 
discovery (Jeffery and Bogyo, 2003; Cravatt et al., 2008). A major advantage of chemical proteomics 
is that once the overall workflow has been established, the methodology can be adapted relatively 
simply and rapidly to different biological systems. This advantage of chemical proteomics has been 
exploited by Wright et al. who used an in house established approach for elucidating the global 
impact of N-myristoyltransferase (NMT)-dependent protein myristoylation (Wright et al., in this 
issue). In their approach, a combination of an alkyne-tagged myristic acid analogue and chemical 
knockdown experiments are used to identify NMT substrates and to quantify their relative 
abundance in diverse biological systems and processes. These studies led for example to the 
elucidation of plasmodial NMT as a potential antimalarial drug target (Wright et al., 2014) or enabled 
the mapping of myristoylation patterns in cancer cells (Thinon et al., 2014).  
Wright et. al. now adapted this approach to investigate the relevance of Leishmania donovani N-
myristoyltransferase (NMT) for parasital protein myristoylation (Wright et al., this issue). L. donovani 
is the causing pathogen of visceral leishmaniasis (VL), the most fatal manifestation of leishmanias 
that results in a systemic infection causing organ swelling, fever and anemia up to organ failures and 
death. Current treatment options are limited and alternative chemotherapeutic approaches are thus 
highly desirable. Although previous molecular and bioinformatics studies suggested that NMT plays 
an important role for proper myristoylation and survival of L. donovani, a deeper understanding of its 
overall contribution to proteome myristoylation and thus drug target potential has not been reached 
so far. They therefore incubated L. donovani promastigotes or amastigotes with the alkyne myristic 
acid analogue, resulting in an alkyne myristate modified lipidome (Figure 1). Subsequent affinity 
capture of these proteins via copper catalyzed cycloaddition (CuAAC) and quantitative mass 
spectrometry permitted a quantitative and global view on L. donovani myristoylation. This approach 
led to a ͚high ĐonfidenĐe͛ identifiĐation of overall 49 myristoylated proteins (including known 
myristoylated substrates such as ARL1 or SMP1) in the amastigote and 113 myristoylated proteins in 
promastigotes. These are many more myristoylated proteins than predicted by bioinformatics 
estimations indicating that protein myristoylation in L. donovani is much more important than 
previously anticipated.  
The analysis further revealed that unexpectedly 59% of the myristate-modified proteins in 
amastigotes and even 78% in promastigotes did not contain an N-terminal glycine residue. This motif 
is however supposed to be an essential motif for NMT-dependent myristoylation, indicating that 
besides NMT further enzymes may contribute to protein myristoylation. To better assess the 
individual contribution of NMT, the authors combined their metabolic labelling in a second step with 
a chemical knockdown approach. To this end, they preincubated L. donovani amastigotes and 
promastigotes with two previously characterized, biochemically equipotent NMT inhibitors that 
however displayed significantly different inhibitory activities on a cellular level. Preincubation of L. 
donovani cultures with both inhibitors led to an efficient reduction of parasital myristoylation in a 
dose-dependent manner that furthermore correlated well with the experimentally determined EC50 
values, thus confirming target engagement of the compounds in living parasites. However, chemical 
knockdown in amastigotes in combination with quantitative proteomics did not lead to a uniform 
reduction in protein myristoylation. Instead, only a subset of 30 proteins (in a high confidence 
interval) were less myristoylated and interestingly all of them carried an N-terminal glycine residue, 
indicating that these 30 proteins are direct NMT substrates. A subsequent GO term analysis of these 
30 proteins then revealed that 50% of identified proteins are of unknown function while the other 
half are involved in highly diverse biological processes such as signal transduction, transport or 
degradation. This indicates that a small molecule-mediated NMT inhibition may have extensive 
implications on L. donovani biology.  
Although additional experiments are required to further validate NMT as a leishmaniasis drug target, 
e.g. to exclude potential off target effects of the NMT inhibitors that might contribute to the 
observed antiparasital effect, the present study elegantly demonstrates the potential of chemical 
proteomics in conjunction with quantitative mass spectrometry to rapidly catalogue post-
translationally modified proteins and to evaluate potential drug targets in various biological systems, 
using one common approach. This study might therefore serve as a blueprint for similar studies on 
other enzymes and/or post-translational modifications that surely will be addressed in the future.  
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Figure 1.  
 
Figure 1. Workflow of the global target identification and chemical knockdown approach.  
Two complementary experiments were performed to assess parasital NMT substrates. For the first 
approach, amastigotes and promastigotes were grown in the presence of YnMyr (alkyne myristic acid 
analogue) or myr (myristic acid). Subsequently, labelled proteins were decorated with AzRB (using 
CuAAC), affinity purified on NeutrAvidin and on-bead digested with trypsin. After LC-MS/MS the 
obtained spectra were searched with MaxQuant using the Andromeda search engine and label free 
quantification turned on. Comparison of the different dataset resulted in a total of 49 high 
confidence (81 total) YnMyr modified proteins in amastigotes and 113 high confidence (134 total) 
proteins in promastigotes. For the second approach, amastigotes were preincubated for 1 h with or 
without the NMT inhibitors and then labelled for 12 h with YnMyr. After work up and mass 
spectrometry, (same as for first approach) the four datasets were statistically compared, resulting in 
the identification of 30 proteins whose intensity was significantly reduced in the presence of the 
NMT inhibitors. These proteins were classified true NMT targets/substrates. 
 
 
